We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-13.94%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.49B
AUM Growth
-$764M
Cap. Flow
-$255M
Cap. Flow %
-10.24%
Top 10 Hldgs %
45.62%
Holding
96
New
13
Increased
17
Reduced
38
Closed
17

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$46.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M
3
MDT icon
Medtronic
MDT
+$39.2M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$37.5M
5
EPZM
Epizyme, Inc
EPZM
+$33.5M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$50M
2
BLUE
bluebird bio
BLUE
+$36.8M
3
ELV icon
Elevance Health
ELV
+$32.6M
4
CNC icon
Centene
CNC
+$32.1M
5
NUVA
NuVasive, Inc.
NUVA
+$31.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.57%
2 Miscellaneous 1.72%
3 Financials 1.69%
4 Energy 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$235M 9.43%
16,459,128
+552,448
+3% +$8.38M
ATRA icon
2
Atara Biotherapeutics
ATRA
$92.3M
$153M 6.17%
176,585
+7,836
+5% +$7.28M
FATE icon
3
Fate Therapeutics
FATE
$291M
$133M 5.35%
10,359,666
– –
XNCR icon
4
Xencor
XNCR
$1.94B
$112M 4.49%
3,084,703
+54,560
+2% +$2M
WVE icon
5
Wave Life Sciences
WVE
$993M
$94.1M 3.78%
2,237,607
-35,700
-2% -$1.59M
ARGX icon
6
argenx
ARGX
$64B
$92.3M 3.71%
960,961
-13,545
-1% -$1.2M
ALLK
7
DELISTED
Allakos
ALLK
$88.8M 3.57%
1,698,648
+238,756
+16% +$12M
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
$79.7M 3.21%
8,323,217
-79,400
-0.9% -$873K
IFRX icon
9
InflaRx
IFRX
$329M
$74M 2.98%
2,035,400
+10,500
+0.5% +$323K
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
$72.9M 2.93%
4,060,529
+2,282,229
+128% +$46.6M
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
$69.1M 2.78%
2,537,300
+363,600
+17% +$10M
ALDR
12
DELISTED
Alder Biopharmaceuticals
ALDR
$66.7M 2.68%
6,505,766
– –
RGNX icon
13
Regenxbio
RGNX
$638M
$56.8M 2.29%
1,354,742
-301,323
-18% -$17.7M
CI icon
14
Cigna
CI
$73.7B
$52.3M 2.11%
275,610
-94,590
-26% -$19.7M
IMGN
15
DELISTED
Immunogen Inc
IMGN
$52.2M 2.1%
10,884,607
-1,424,428
-12% -$8.64M
BOLD
16
DELISTED
Audentes Therapeutics, Inc
BOLD
$49.1M 1.97%
2,301,667
+58,311
+3% +$1.5M
LIVN icon
17
LivaNova
LIVN
$4.43B
$47.1M 1.89%
514,987
-84,301
-14% -$9.05M
BMY icon
18
Bristol-Myers Squibb
BMY
$136B
$44.4M 1.79%
+854,700
New +$45.9M
EHTH icon
19
eHealth
EHTH
$38.4M
$41.9M 1.69%
1,091,395
-381,200
-26% -$12.8M
XERS icon
20
Xeris Biopharma Holdings
XERS
$1.55B
$41M 1.65%
2,412,641
+1
+0% +$20
EPZM
21
DELISTED
Epizyme, Inc
EPZM
$40.9M 1.64%
6,637,278
+4,389,089
+195% +$33.5M
SRRK icon
22
Scholar Rock
SRRK
$7.04B
$40.5M 1.63%
1,761,407
-11,700
-0.7% -$265K
TNDM icon
23
Tandem Diabetes Care
TNDM
$1.49B
$39.5M 1.59%
1,039,750
-29,920
-3% -$1.06M
MDT icon
24
Medtronic
MDT
$117B
$38.2M 1.54%
+419,900
New +$39.2M
QURE icon
25
uniQure
QURE
$3.38B
$37.6M 1.51%
1,303,422
-336,478
-21% -$9.36M
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2018 Portfolio in Review

As of Q4 2018, Redmile Group held 96 positions worth $2.49B, down 24% from $3.25B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group withdrew a net $255M in Q4 2018, closing 17 positions and reducing 38 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $50M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Redmile Group opened a new position in Bristol-Myers Squibb worth $44.4M.

  • Redmile Group's largest Q4 2018 buy was Bristol-Myers Squibb: 854,700 shares worth $44.4M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2018, an estimated $46.6M increase.
  • Redmile Group's biggest Q4 2018 reduction was Elevance Health, cutting an estimated $32.6M.
  • Redmile Group fully exited Wellcare Health Plans, Inc. in Q4 2018, selling an estimated $50M.
  • Redmile Group's ten largest holdings make up 46% of its $2.49B portfolio in Q4 2018.
  • Redmile Group opened 13 new positions and closed 17 in Q4 2018.
  • Redmile Group's portfolio value fell 24% quarter-over-quarter to $2.49B.

Based on Redmile Group's 13F filing for Q4 2018, filed 14 Feb 2019.